Stage IV Favorable Histology Wilms Tumor — What to Do When Initial Therapy Does Not Achieve Complete Lung Response at 6 Weeks

This protocol addresses children with stage IV favorable histology Wilms tumor (FHWT), classified as higher risk, who present with metastatic disease — most commonly to the lungs — and in whom the initial chemotherapy course has not produced a complete pulmonary response by 6 weeks.

Clinical Scenario

Patients are children with stage IV FHWT (higher risk) and lung-predominant metastatic disease. For this population, initial therapy with DD4A — a multi-agent chemotherapy regimen administered over 24 weeks — is the recommended first-line approach. Complete response of pulmonary lesions at 6 weeks serves as the critical early benchmark for determining subsequent management.

Escalation Trigger

When initial DD4A therapy does not achieve complete response of lung-only metastases at the 6-week assessment, a change in strategy is indicated. This failure to meet the early pulmonary response target defines the setting for which this next-step protocol applies.

Next-Step Approach (Partial Overview)

The recommended response is a switch to a more intensive, augmented combination chemotherapy regimen — an approach that broadens the number of agents and extends the treatment structure beyond the initial regimen. The complete sequence, agent selection, and scheduling details are available in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DD4A is recommended as initial therapy for patients with stage IV FHWT classified as higher risk.

Switching to augmented therapy with regimen M is recommended for patients with (1) combined LOH of 1p and 16q; or (2) lung metastases that have slow incomplete response after 6 weeks of chemotherapy.

DOI: 10.6004/jnccn.2021.0037

View source ↗